Editas Medicine, Inc. (EDIT)

Market Cap	294.94M
Revenue (ttm)	38.90M
Net Income (ttm)	-236.86M
Shares Out	89.92M
EPS (ttm)	-2.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,909,504
Open	3.545
Previous Close	3.720
Day's Range	3.145 - 3.620
52-Week Range	0.910 - 4.537
Beta	2.18
Analysts	Buy
Price Target	4.56 (+39.02%)
Earnings Date	Oct 31, 2025

About EDIT

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporate...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 3, 2016
• Employees: 246
• Stock Exchange: NASDAQ
• Ticker Symbol: EDIT
• Website: https://www.editasmedicine.com

Financial Performance

In 2024, Editas Medicine's revenue was $32.31 million, a decrease of -58.64% compared to the previous year's $78.12 million. Losses were -$237.09 million, 54.7% more than in 2023.

Analyst Summary

According to 11 analysts, the average rating for EDIT stock is "Buy." The 12-month stock price target is $4.56, which is an increase of 39.02% from the latest price.

Price Target

$4.56

(39.02% upside)

Analyst Consensus: Buy